Her main research concerns Antibody, Virology, Epitope, Neutralization and Immunology. Many of her studies on Antibody involve topics that are commonly interrelated, such as Viral load. Her Virology study integrates concerns from other disciplines, such as Complementarity determining region and Pneumonia.
Her Epitope research is multidisciplinary, incorporating elements of Protein structure, Viral entry and Stereochemistry. Her Neutralization research incorporates themes from Molecular biology, Glycoprotein and Monoclonal antibody. Her work in Glycoprotein covers topics such as CD4 antigen which are related to areas like Viral envelope.
Nicole A. Doria-Rose focuses on Antibody, Virology, Neutralization, Epitope and Neutralizing antibody. She interconnects Virus, Lineage and Glycan in the investigation of issues within Antibody. Her Virology study combines topics from a wide range of disciplines, such as Immunization, Immune system, Glycoprotein and Immunogen, Monoclonal antibody.
Her study in Neutralization is interdisciplinary in nature, drawing from both Viral envelope, Gp41, Potency, Molecular biology and Protein structure. Her work carried out in the field of Epitope brings together such families of science as Viral entry, Glycosylation and Binding site. The Neutralizing antibody study combines topics in areas such as Pathogen, Immunopathology, Immunogenicity and Vaccination.
Nicole A. Doria-Rose mainly focuses on Antibody, Virology, Vaccination, Neutralization and Neutralizing antibody. Her Epitope and Somatic hypermutation study in the realm of Antibody connects with subjects such as Severe acute respiratory syndrome coronavirus 2. In her study, Antigenicity is inextricably linked to Binding site, which falls within the broad field of Epitope.
The study incorporates disciplines such as HIV vaccine, Priming, Immunization, Immune system and Immunogen in addition to Virology. Her Vaccination course of study focuses on Antibody Repertoire and Respiratory syncytial virus, Protein subunit, Glycoprotein and Virus. As part of her studies on Neutralization, Nicole A. Doria-Rose frequently links adjacent subjects like Viremia.
Her primary areas of study are Antibody, Messenger RNA, Virology, Severe acute respiratory syndrome coronavirus 2 and Neutralizing antibody. Her Antibody study combines topics from a wide range of disciplines, such as Lineage and Cell biology. Her Severe acute respiratory syndrome coronavirus 2 study overlaps with 2019-20 coronavirus outbreak, Vaccination and Immunization.
Her Immunization research is multidisciplinary, incorporating perspectives in Viral replication, Viral load and Pneumonia. Her Neutralizing antibody study combines topics in areas such as Pathogen, Immunopathology and Immunogenicity. Her Pathogen research incorporates themes from Mutation, T cell, CD8, Cytotoxic T cell and Immunogen.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Lisa A. Jackson;Evan J. Anderson;Nadine G. Rouphael;Paul C. Roberts.
The New England Journal of Medicine (2020)
Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1
Xueling Wu;Zhi Yong Yang;Yuxing Li;Carl Magnus Hogerkorp.
Science (2010)
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.
Evan J. Anderson;Nadine G. Rouphael;Alicia T. Widge;Lisa A. Jackson.
The New England Journal of Medicine (2020)
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody
Jinghe Huang;Gilad Ofek;Leo Laub;Mark K. Louder.
Nature (2012)
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.
Kizzmekia S. Corbett;Darin K. Edwards;Sarah R. Leist;Olubukola M. Abiona.
Nature (2020)
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.
Kizzmekia S Corbett;Barbara Flynn;Kathryn E Foulds;Joseph R Francica.
The New England Journal of Medicine (2020)
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.
Nicole A. Doria-Rose;Chaim A. Schramm;Jason Gorman;Penny L. Moore.
Nature (2014)
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.
Alicia T. Widge;Nadine G. Rouphael;Lisa A. Jackson;Evan J. Anderson.
The New England Journal of Medicine (2021)
Broad and potent HIV-1 neutralization by a human antibody that binds the gp41–gp120 interface
Jinghe Huang;Byong H. Kang;Marie Pancera;Jeong Hyun Lee.
Nature (2014)
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19.
Nicole Doria-Rose;Mehul S. Suthar;Mat Makowski;Sarah O’Connell.
The New England Journal of Medicine (2021)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
National Institute of Allergy and Infectious Diseases
National Institutes of Health
National Institute of Allergy and Infectious Diseases
National Institute of Allergy and Infectious Diseases
Columbia University
Moderna Therapeutics (United States)
National Institutes of Health
National Institute of Allergy and Infectious Diseases
National Institute of Allergy and Infectious Diseases
National Institute of Allergy and Infectious Diseases
University of Sussex
RWTH Aachen University
University of California, Berkeley
Agency for Science, Technology and Research
University of South Carolina
University of Parma
University of Cambridge
Tohoku University
National Academies of Sciences, Engineering, and Medicine
University of Pavia
University of Erlangen-Nuremberg
National Institute of Geophysics and Volcanology
University of Chicago
University of Louisiana at Lafayette
Vita-Salute San Raffaele University
University College London